Single-cell developmental classification of B cell precursor acute lymphoblastic leukemia at diagnosis reveals predictors of relapse
Data files
Jul 11, 2025 version files 5.86 GB
-
ddpr_data.zip
5.86 GB
-
README.md
19.95 KB
Abstract
This dataset supports the publication "Single-Cell Developmental Classification of B-Cell Precursor Acute Lymphoblastic Leukemia at Diagnosis Reveals Predictors of Relapse" (Nature Medicine, 2018). It contains single-cell mass cytometry measurements from 60 pediatric patients diagnosed with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), along with data from 5 healthy bone marrow donors. Using a panel of 35 surface and intracellular proteins, each leukemia cell was classified into its closest developmental B-cell stage using a supervised single-cell developmental classifier. Features derived from these classified cell populations—including protein expression levels and signaling responses under basal and perturbed conditions—were used to construct a machine learning model (Developmentally Dependent Predictor of Relapse, or DDPR) that stratifies patients at diagnosis based on future risk of relapse. This dataset includes raw, bead-normalized ion count data. It enables exploration of developmental heterogeneity in BCP-ALL and provides a resource for studying relapse-associated signaling states in leukemic populations.
Dataset DOI: 10.5061/dryad.pvmcvdnxc
Description of the data and file structure
DDPR
Developmentally Dependent Predictor of Relapse
This repository contains the original mass cytometry (.FCS) data generated for the DDPR project, as described in:
Good et al. Single-Cell Developmental Classification of B-Cell Precursor Acute Lymphoblastic Leukemia at Diagnosis Reveals Predictors of Relapse, Nature Medicine, 2018.
Overview
This dataset consists of single-cell mass cytometry (CyTOF) data from 60 pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) diagnostic samples and 5 healthy adult bone marrow donors. The study used a 35-marker antibody panel to profile surface and intracellular protein expression, including basal and perturbed signaling states, at single-cell resolution.
Each leukemia sample has been:
- Bead-normalized (Finck et al., Cytometry A, 2013)
- Debarcoded using palladium-based cell barcoding (Zunder et al., Nat Protoc, 2015)
- Gated on lineage-negative (Lin⁻) B-lineage cells, excluding T cells, myeloid cells, and other lineages (see Supplementary Fig. 1a of the paper for gating strategy)
Contents
- Bead-normalized, debarcoded FCS files for all 60 patients and 5 healthy controls (in a single zip file)
- Samples stained with a panel of 35 antibodies, including markers of B-cell development and intracellular signaling (see Supplementary Table 2)
- Samples treated with various ex vivo perturbations, including:
- Pervanadate
- B-cell receptor (BCR) crosslinking
- IL-7
- Thymic stromal lymphopoietin (TSLP)
- BEZ235 (PI3K/mTOR inhibitor)
- Dasatinib (ABL/SRC kinase inhibitor)
- Tofacitinib (JAK inhibitor)
(see Supplementary Table 3 for concentrations and timepoints)
Clinical Metadata
Patient metadata are provided in Supplementary Table 1 of Good and Sarno et al., including:
- Diagnostic cytogenetics
- Age and WBC count at diagnosis
- Minimal residual disease (MRD) risk
- Final risk group (per AIEOP-BFM 2000 protocol)
- Relapse status and time-to-relapse or last follow-up
Median follow-up time: 5.5 years
Relapse occurred in 17 of 54 patients with ≥3 years of follow-up.
Citation
If using this dataset, consider citing the original paper:
Good Z, Sarno J, Jager A, et al. Single-Cell Developmental Classification of B-Cell Precursor Acute Lymphoblastic Leukemia at Diagnosis Reveals Predictors of Relapse. Nat Med. 2018;24(4):474–483. doi:10.1038/nm.4505
Files and variables
File: ddpr_data.zip
Description:
Files and Variables
This zip file contains mass cytometry (.fcs) files from a study of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and healthy bone marrow controls. These files are bead-normalized, debarcoded, and gated on lineage-negative (Lin⁻) B-lineage cells. Each file corresponds to a specific sample (healthy donor or patient) and experimental condition.
All data files are in .fcs
(Flow Cytometry Standard) format and are organized by:
- Donor/sample ID (e.g.,
UPN1
,UPN35
,Healthy3
) - Stimulation or perturbation condition (e.g.,
Basal
,IL-7
,Pervanadate
,BCR-Crosslink
,Dasatinib
,BEZ-235
,Tofacitinib
,TSLP
)
🗃️ File Naming Convention
[SampleID]_[Condition].fcs
SampleID
: UPN codes (e.g.,UPN4
,UPN35-Relapse
) orHealthy[1–5]
Condition
: The stimulation or treatment applied:Basal
: No stimulationBCR-Crosslink
: B-cell receptor engagementIL-7
,TSLP
: Cytokine stimulationPervanadate
: Broad phosphatase inhibitionBEZ-235
: PI3K/mTOR inhibitionDasatinib
: ABL/Src family kinase inhibitionTofacitinib
: JAK inhibition
For some samples, especially healthy donors, files are split into parts (e.g., Healthy3_Basal_Part1.fcs
), which can be merged during downstream analysis.
.FCS Files
- 525
.fcs
files- 60+ unique UPN patient samples
- 5 healthy donor samples
- Multiple perturbation conditions per sample
📈 Variables (Channels)
Each .fcs
file contains single-cell expression measurements for the following:
🔬 Cell Identification and Quality Control
191Ir
,193Ir
: DNA intercalators (nuclear content)195Pt
: Cisplatin (viability stain)Event_length
: Pulse width for singlet discrimination
🔄 Lineage Gating Markers
CD3e
,CD16
,CD33
,CD61
,CD235a
,CD38High
: Excluded during lineage-negative gating
📊 Phenotypic and Developmental Markers (subset)
CD10
,CD19
,CD20
,CD22
,CD24
,CD34
,CD38
,CD43
,CD45
,CD58
,CD127
HLA-DR
,TdT
,PAX5
,IKAROS
,RAG1
,Tslpr
,CD79b
,CD179a
,CD179b
IgHi
,IgHs
,Ki-67
⚡ Signaling Markers (phospho-proteins)
pS6
,p4EBP1
,pSTAT5
,pSYK
,pCREB
,pPLCγ2
,pAKT
,pERK1/2
,pIKAROS
🧪 Units of Measurement
- Protein expression: signal intensity (mass cytometry ion counts)
- Each row in an
.fcs
file = one single cell - Each column = measured parameter (as described above)
⚠️ Missing Values
.fcs
files do not use explicit NA markers- Undetected or low-signal proteins will have low numeric values (typically near 0)
- No rows are removed; all single-cell events after gating are preserved
🔗 Metadata Reference
Sample-level metadata (age, diagnosis, relapse status, risk stratification, cytogenetics) are described in:
Good Z, et al. Single-Cell Developmental Classification of B-Cell Precursor Acute Lymphoblastic Leukemia at Diagnosis Reveals Predictors of Relapse, Nature Medicine, 2018.
https://doi.org/10.1038/nm.4505
For antibody panel details and perturbation conditions, refer to Supplementary Tables 2 and 3 of the above publication.
Complete File List:
Healthy1_BCR-Crosslink.fcs UPN29_IL-7.fcs
Healthy1_Basal.fcs UPN29_Pervanadate.fcs
Healthy1_IL-7.fcs UPN29_TSLP.fcs
Healthy1_Pervanadate.fcs UPN29_Tofacitinib.fcs
Healthy1_TSLP.fcs UPN2_BCR-Crosslink.fcs
Healthy2_BCR-Crosslink_Part1.fcs UPN2_BEZ-235.fcs
Healthy2_BCR-Crosslink_Part2.fcs UPN2_Basal.fcs
Healthy2_BCR-Crosslink_Part3.fcs UPN2_Dasatinib.fcs
Healthy2_BCR-Crosslink_Part4.fcs UPN2_IL-7.fcs
Healthy2_Basal_Part1.fcs UPN2_Pervanadate.fcs
Healthy2_Basal_Part2.fcs UPN2_TSLP.fcs
Healthy2_Basal_Part3.fcs UPN2_Tofacitinib.fcs
Healthy2_Basal_Part4.fcs UPN30_BCR-Crosslink.fcs
Healthy2_IL-7_Part1.fcs UPN30_BEZ-235.fcs
Healthy2_IL-7_Part2.fcs UPN30_Basal.fcs
Healthy2_IL-7_Part3.fcs UPN30_Dasatinib.fcs
Healthy2_IL-7_Part4.fcs UPN30_IL-7.fcs
Healthy2_Pervanadate.fcs UPN30_Pervanadate.fcs
Healthy2_TSLP_Part1.fcs UPN30_TSLP.fcs
Healthy2_TSLP_Part2.fcs UPN30_Tofacitinib.fcs
Healthy2_TSLP_Part3.fcs UPN31_BCR-Crosslink.fcs
Healthy2_TSLP_Part4.fcs UPN31_BEZ-235.fcs
Healthy3_BCR-Crosslink_Part1.fcs UPN31_Basal.fcs
Healthy3_BCR-Crosslink_Part2.fcs UPN31_Dasatinib.fcs
Healthy3_BCR-Crosslink_Part3.fcs UPN31_IL-7.fcs
Healthy3_BCR-Crosslink_Part4.fcs UPN31_Pervanadate.fcs
Healthy3_BCR-Crosslink_Part5.fcs UPN31_TSLP.fcs
Healthy3_BCR-Crosslink_Part6.fcs UPN31_Tofacitinib.fcs
Healthy3_BCR-Crosslink_Part7.fcs UPN35-Relapse_BCR-Crosslink.fcs
Healthy3_BCR-Crosslink_Part8.fcs UPN35-Relapse_BEZ-235.fcs
Healthy3_BCR-Crosslink_Part9.fcs UPN35-Relapse_Basal.fcs
Healthy3_BEZ-235_Part1.fcs UPN35-Relapse_Dasatinib.fcs
Healthy3_BEZ-235_Part2.fcs UPN35_BCR-Crosslink.fcs
Healthy3_BEZ-235_Part3.fcs UPN35_BEZ-235.fcs
Healthy3_Basal_Part1.fcs UPN35_Basal.fcs
Healthy3_Basal_Part10.fcs UPN35_Dasatinib.fcs
Healthy3_Basal_Part2.fcs UPN3_BCR-Crosslink.fcs
Healthy3_Basal_Part3.fcs UPN3_BEZ-235.fcs
Healthy3_Basal_Part4.fcs UPN3_Basal.fcs
Healthy3_Basal_Part5.fcs UPN3_Dasatinib.fcs
Healthy3_Basal_Part6.fcs UPN3_IL-7.fcs
Healthy3_Basal_Part7.fcs UPN3_Pervanadate.fcs
Healthy3_Basal_Part8.fcs UPN3_TSLP.fcs
Healthy3_Basal_Part9.fcs UPN3_Tofacitinib.fcs
Healthy3_Dasatinib_Part1.fcs UPN45-Relapse_BCR-Crosslink.fcs
Healthy3_Dasatinib_Part2.fcs UPN45-Relapse_BEZ-235.fcs
Healthy3_IL-7_Part1.fcs UPN45-Relapse_Basal.fcs
Healthy3_IL-7_Part2.fcs UPN45-Relapse_Dasatinib.fcs
Healthy3_IL-7_Part3.fcs UPN45_BCR-Crosslink.fcs
Healthy3_IL-7_Part4.fcs UPN45_BEZ-235.fcs
Healthy3_IL-7_Part5.fcs UPN45_Basal.fcs
Healthy3_IL-7_Part6.fcs UPN45_Dasatinib.fcs
Healthy3_IL-7_Part7.fcs UPN47_BCR-Crosslink.fcs
Healthy3_IL-7_Part8.fcs UPN47_BEZ-235.fcs
Healthy3_IL-7_Part9.fcs UPN47_Basal.fcs
Healthy3_Pervanadate_Part1.fcs UPN47_Dasatinib.fcs
Healthy3_Pervanadate_Part2.fcs UPN47_IL-7.fcs
Healthy3_Pervanadate_Part3.fcs UPN47_Pervanadate.fcs
Healthy3_TSLP_Part1.fcs UPN47_TSLP.fcs
Healthy3_TSLP_Part2.fcs UPN47_Tofacitinib.fcs
Healthy3_TSLP_Part3.fcs UPN48_BCR-Crosslink.fcs
Healthy3_TSLP_Part4.fcs UPN48_BEZ-235.fcs
Healthy3_TSLP_Part5.fcs UPN48_Basal.fcs
Healthy3_TSLP_Part6.fcs UPN48_Dasatinib.fcs
Healthy3_TSLP_Part7.fcs UPN48_IL-7.fcs
Healthy3_TSLP_Part8.fcs UPN48_Pervanadate.fcs
Healthy3_TSLP_Part9.fcs UPN48_TSLP.fcs
Healthy3_Tofacitinib_Part1.fcs UPN48_Tofacitinib.fcs
Healthy3_Tofacitinib_Part2.fcs UPN49_BCR-Crosslink.fcs
Healthy3_Tofacitinib_Part3.fcs UPN49_BEZ-235.fcs
Healthy3_Tofacitinib_Part4.fcs UPN49_Basal.fcs
Healthy4_BCR-Crosslink_Part1.fcs UPN49_Dasatinib.fcs
Healthy4_BCR-Crosslink_Part2.fcs UPN49_IL-7.fcs
Healthy4_BCR-Crosslink_Part3.fcs UPN49_Pervanadate.fcs
Healthy4_BCR-Crosslink_Part4.fcs UPN49_TSLP.fcs
Healthy4_BCR-Crosslink_Part5.fcs UPN49_Tofacitinib.fcs
Healthy4_BCR-Crosslink_Part6.fcs UPN4_BCR-Crosslink.fcs
Healthy4_Basal_Part1.fcs UPN4_BEZ-235.fcs
Healthy4_Basal_Part2.fcs UPN4_Basal.fcs
Healthy4_Basal_Part3.fcs UPN4_Dasatinib.fcs
Healthy4_Basal_Part4.fcs UPN4_IL-7.fcs
Healthy4_Basal_Part5.fcs UPN4_Pervanadate.fcs
Healthy4_Basal_Part6.fcs UPN4_TSLP.fcs
Healthy4_IL-7_Part1.fcs UPN4_Tofacitinib.fcs
Healthy4_IL-7_Part2.fcs UPN50_BCR-Crosslink.fcs
Healthy4_IL-7_Part3.fcs UPN50_BEZ-235.fcs
Healthy4_IL-7_Part4.fcs UPN50_Basal.fcs
Healthy4_IL-7_Part5.fcs UPN50_Dasatinib.fcs
Healthy4_IL-7_Part6.fcs UPN50_IL-7.fcs
Healthy4_Pervanadate.fcs UPN50_Pervanadate.fcs
Healthy4_TSLP_Part1.fcs UPN50_TSLP.fcs
Healthy4_TSLP_Part2.fcs UPN50_Tofacitinib.fcs
Healthy5_Basal_Part1.fcs UPN51_BCR-Crosslink.fcs
Healthy5_Basal_Part2.fcs UPN51_BEZ-235.fcs
Healthy5_Basal_Part3.fcs UPN51_Basal.fcs
UPN1-Relapse_BCR-Crosslink.fcs UPN51_Dasatinib.fcs
UPN1-Relapse_BEZ-235.fcs UPN51_IL-7.fcs
UPN1-Relapse_Basal.fcs UPN51_Pervanadate.fcs
UPN1-Relapse_Dasatinib.fcs UPN51_TSLP.fcs
UPN10-Relapse_BCR-Crosslink.fcs UPN51_Tofacitinib.fcs
UPN10-Relapse_BEZ-235.fcs UPN52_BCR-Crosslink.fcs
UPN10-Relapse_Basal.fcs UPN52_BEZ-235.fcs
UPN10-Relapse_Dasatinib.fcs UPN52_Basal.fcs
UPN10_BCR-Crosslink.fcs UPN52_Dasatinib.fcs
UPN10_BEZ-235.fcs UPN52_IL-7.fcs
UPN10_Basal.fcs UPN52_Pervanadate.fcs
UPN10_Dasatinib.fcs UPN52_TSLP.fcs
UPN11_BCR-Crosslink.fcs UPN52_Tofacitinib.fcs
UPN11_BEZ-235.fcs UPN53_BCR-Crosslink.fcs
UPN11_Basal.fcs UPN53_BEZ-235.fcs
UPN11_Dasatinib.fcs UPN53_Basal.fcs
UPN11_IL-7.fcs UPN53_Dasatinib.fcs
UPN11_Pervanadate.fcs UPN53_IL-7.fcs
UPN11_TSLP.fcs UPN53_Pervanadate.fcs
UPN11_Tofacitinib.fcs UPN53_TSLP.fcs
UPN12_BCR-Crosslink.fcs UPN53_Tofacitinib.fcs
UPN12_BEZ-235.fcs UPN54_BCR-Crosslink.fcs
UPN12_Basal.fcs UPN54_BEZ-235.fcs
UPN12_Dasatinib.fcs UPN54_Basal.fcs
UPN12_IL-7.fcs UPN54_Dasatinib.fcs
UPN12_Pervanadate.fcs UPN54_IL-7.fcs
UPN12_TSLP.fcs UPN54_Pervanadate.fcs
UPN12_Tofacitinib.fcs UPN54_TSLP.fcs
UPN13_BCR-Crosslink.fcs UPN54_Tofacitinib.fcs
UPN13_BEZ-235.fcs UPN55_BCR-Crosslink.fcs
UPN13_Basal.fcs UPN55_BEZ-235.fcs
UPN13_Dasatinib.fcs UPN55_Basal.fcs
UPN13_IL-7.fcs UPN55_Dasatinib.fcs
UPN13_Pervanadate.fcs UPN55_IL-7.fcs
UPN13_TSLP.fcs UPN55_Pervanadate.fcs
UPN13_Tofacitinib.fcs UPN55_TSLP.fcs
UPN14_BCR-Crosslink.fcs UPN55_Tofacitinib.fcs
UPN14_BEZ-235.fcs UPN56_BCR-Crosslink.fcs
UPN14_Basal.fcs UPN56_BEZ-235.fcs
UPN14_Dasatinib.fcs UPN56_Basal.fcs
UPN14_IL-7.fcs UPN56_Dasatinib.fcs
UPN14_Pervanadate.fcs UPN56_IL-7.fcs
UPN14_TSLP.fcs UPN56_Pervanadate.fcs
UPN14_Tofacitinib.fcs UPN56_TSLP.fcs
UPN15_BCR-Crosslink.fcs UPN56_Tofacitinib.fcs
UPN15_BEZ-235.fcs UPN57_BCR-Crosslink.fcs
UPN15_Basal.fcs UPN57_BEZ-235.fcs
UPN15_Dasatinib.fcs UPN57_Basal.fcs
UPN15_IL-7.fcs UPN57_Dasatinib.fcs
UPN15_Pervanadate.fcs UPN57_IL-7.fcs
UPN15_TSLP.fcs UPN57_Pervanadate.fcs
UPN15_Tofacitinib.fcs UPN57_TSLP.fcs
UPN16_BCR-Crosslink.fcs UPN57_Tofacitinib.fcs
UPN16_BEZ-235.fcs UPN58_BCR-Crosslink.fcs
UPN16_Basal.fcs UPN58_BEZ-235.fcs
UPN16_Dasatinib.fcs UPN58_Basal.fcs
UPN16_IL-7.fcs UPN58_Dasatinib.fcs
UPN16_Pervanadate.fcs UPN58_IL-7.fcs
UPN16_TSLP.fcs UPN58_Pervanadate.fcs
UPN16_Tofacitinib.fcs UPN58_TSLP.fcs
UPN17_BCR-Crosslink.fcs UPN58_Tofacitinib.fcs
UPN17_BEZ-235.fcs UPN5_BCR-Crosslink.fcs
UPN17_Basal.fcs UPN5_BEZ-235.fcs
UPN17_Dasatinib.fcs UPN5_Basal.fcs
UPN17_IL-7.fcs UPN5_Dasatinib.fcs
UPN17_Pervanadate.fcs UPN5_IL-7.fcs
UPN17_TSLP.fcs UPN5_Pervanadate.fcs
UPN17_Tofacitinib.fcs UPN5_TSLP.fcs
UPN18_BCR-Crosslink.fcs UPN5_Tofacitinib.fcs
UPN18_BEZ-235.fcs UPN60-Blood_Basal.fcs
UPN18_Basal.fcs UPN60_Basal.fcs
UPN18_Dasatinib.fcs UPN61-Blood_Basal.fcs
UPN18_IL-7.fcs UPN62-Blood_Basal.fcs
UPN18_Pervanadate.fcs UPN62_Basal.fcs
UPN18_TSLP.fcs UPN63-Blood_Basal.fcs
UPN18_Tofacitinib.fcs UPN63_Basal.fcs
UPN19_BCR-Crosslink.fcs UPN64-Blood_Basal.fcs
UPN19_BEZ-235.fcs UPN65-Blood_Basal.fcs
UPN19_Basal.fcs UPN67_BCR-Crosslink.fcs
UPN19_Dasatinib.fcs UPN67_BEZ-235.fcs
UPN19_IL-7.fcs UPN67_Basal.fcs
UPN19_Pervanadate.fcs UPN67_Dasatinib.fcs
UPN19_TSLP.fcs UPN67_IL-7.fcs
UPN19_Tofacitinib.fcs UPN67_Pervanadate.fcs
UPN1_BCR-Crosslink.fcs UPN67_TSLP.fcs
UPN1_BEZ-235.fcs UPN67_Tofacitinib.fcs
UPN1_Basal.fcs UPN68_BCR-Crosslink.fcs
UPN1_Dasatinib.fcs UPN68_BEZ-235.fcs
UPN1_IL-7.fcs UPN68_Basal.fcs
UPN1_Pervanadate.fcs UPN68_Dasatinib.fcs
UPN1_TSLP.fcs UPN68_IL-7.fcs
UPN1_Tofacitinib.fcs UPN68_Pervanadate.fcs
UPN20_BCR-Crosslink.fcs UPN68_TSLP.fcs
UPN20_BEZ-235.fcs UPN68_Tofacitinib.fcs
UPN20_Basal.fcs UPN69_BCR-Crosslink.fcs
UPN20_Dasatinib.fcs UPN69_BEZ-235.fcs
UPN20_IL-7.fcs UPN69_Basal.fcs
UPN20_Pervanadate.fcs UPN69_Dasatinib.fcs
UPN20_TSLP.fcs UPN69_IL-7.fcs
UPN20_Tofacitinib.fcs UPN69_Pervanadate.fcs
UPN21_BCR-Crosslink.fcs UPN69_TSLP.fcs
UPN21_BEZ-235.fcs UPN69_Tofacitinib.fcs
UPN21_Basal.fcs UPN6_BCR-Crosslink.fcs
UPN21_Dasatinib.fcs UPN6_BEZ-235.fcs
UPN21_IL-7.fcs UPN6_Basal.fcs
UPN21_Pervanadate.fcs UPN6_Dasatinib.fcs
UPN21_TSLP.fcs UPN6_IL-7.fcs
UPN21_Tofacitinib.fcs UPN6_Pervanadate.fcs
UPN22-Relapse_BCR-Crosslink.fcs UPN6_TSLP.fcs
UPN22-Relapse_BEZ-235.fcs UPN6_Tofacitinib.fcs
UPN22-Relapse_Basal.fcs UPN7_BCR-Crosslink.fcs
UPN22-Relapse_Dasatinib.fcs UPN7_BEZ-235.fcs
UPN22_BCR-Crosslink.fcs UPN7_Basal.fcs
UPN22_BEZ-235.fcs UPN7_Dasatinib.fcs
UPN22_Basal.fcs UPN7_IL-7.fcs
UPN22_Dasatinib.fcs UPN7_Pervanadate.fcs
UPN23_BCR-Crosslink.fcs UPN7_TSLP.fcs
UPN23_BEZ-235.fcs UPN7_Tofacitinib.fcs
UPN23_Basal.fcs UPN8_BCR-Crosslink.fcs
UPN23_Dasatinib.fcs UPN8_BEZ-235.fcs
UPN23_IL-7.fcs UPN8_Basal.fcs
UPN23_Pervanadate.fcs UPN8_Dasatinib.fcs
UPN23_TSLP.fcs UPN8_IL-7.fcs
UPN23_Tofacitinib.fcs UPN8_Pervanadate.fcs
UPN24_BCR-Crosslink.fcs UPN8_TSLP.fcs
UPN24_BEZ-235.fcs UPN8_Tofacitinib.fcs
UPN24_Basal.fcs UPN90-Relapse_Basal.fcs
UPN24_Dasatinib.fcs UPN90-Relapse_Dasatinib.fcs
UPN24_IL-7.fcs UPN90-Relapse_IL-7.fcs
UPN24_Pervanadate.fcs UPN90_Basal.fcs
UPN24_TSLP.fcs UPN90_Dasatinib.fcs
UPN24_Tofacitinib.fcs UPN90_IL-7.fcs
UPN25_BCR-Crosslink.fcs UPN91_Dasatinib.fcs
UPN25_BEZ-235.fcs UPN91_IL-7.fcs
UPN25_Basal.fcs UPN91_basal.fcs
UPN25_Dasatinib.fcs UPN92_Basal.fcs
UPN25_IL-7.fcs UPN92_Dasatinib.fcs
UPN25_Pervanadate.fcs UPN92_IL-7.fcs
UPN25_TSLP.fcs UPN93_Basal.fcs
UPN25_Tofacitinib.fcs UPN93_Dasatinib.fcs
UPN26_BCR-Crosslink.fcs UPN93_IL-7.fcs
UPN26_BEZ-235.fcs UPN94_Basal.fcs
UPN26_Basal.fcs UPN94_Dasatinib.fcs
UPN26_Dasatinib.fcs UPN94_IL-7.fcs
UPN26_IL-7.fcs UPN95-Relapse_Basal.fcs
UPN26_Pervanadate.fcs UPN95-Relapse_Dasatinib.fcs
UPN26_TSLP.fcs UPN95-Relapse_IL-7.fcs
UPN26_Tofacitinib.fcs UPN95_Basal.fcs
UPN27_BCR-Crosslink.fcs UPN95_Dasatinib.fcs
UPN27_BEZ-235.fcs UPN95_IL-7.fcs
UPN27_Basal.fcs UPN96_Basal.fcs
UPN27_Dasatinib.fcs UPN96_Dasatinib.fcs
UPN27_IL-7.fcs UPN96_IL-7.fcs
UPN27_Pervanadate.fcs UPN97_Basal.fcs
UPN27_TSLP.fcs UPN97_Dasatinib.fcs
UPN27_Tofacitinib.fcs UPN97_IL-7.fcs
UPN28_BCR-Crosslink.fcs UPN98_Basal.fcs
UPN28_BEZ-235.fcs UPN98_Dasatinib.fcs
UPN28_Basal.fcs UPN98_IL-7.fcs
UPN28_Dasatinib.fcs UPN9_BCR-Crosslink.fcs
UPN28_IL-7.fcs UPN9_BEZ-235.fcs
UPN28_Pervanadate.fcs UPN9_Basal.fcs
UPN28_TSLP.fcs UPN9_Dasatinib.fcs
UPN28_Tofacitinib.fcs UPN9_IL-7.fcs
UPN29_BCR-Crosslink.fcs UPN9_Pervanadate.fcs
UPN29_BEZ-235.fcs UPN9_TSLP.fcs
UPN29_Basal.fcs UPN9_Tofacitinib.fcs
UPN29_Dasatinib.fcs
Code/software
Software and Workflow
The data files are in Flow Cytometry Standard (.fcs) format and can be analyzed using free, open-source software. Due to the complexity of high-dimensional cytometry data, we recommend using code-based analysis workflows under the supervision of a trained biostatistician to explore these data.
R
We recommend using the following R packages:
flowCore
: for reading and preprocessing.fcs
filestidyflowcore
: for tidyverse-style workflows with flow cytometry datatidytof
: for downstream analysis, including clustering and visualization
Python
For Python users, we recommend:
pytometry
: for reading, transforming, and analyzing.fcs
files using the Scanpy ecosystem
These packages allow users to load, subset, and analyze single-cell protein expression data from mass cytometry experiments. No analysis scripts are included in this dataset submission.
Access information
Other publicly accessible locations of the data:
Data was derived from the following sources:
Human subjects data
All human subjects data used in this study were obtained under protocols approved by the Institutional Review Boards at Stanford University and the University of Milan Bicocca. Written informed consent was obtained from the parents or legal guardians of all pediatric participants, including consent for future research use and public data sharing of de-identified samples.
The data submitted to Dryad have been fully de-identified in accordance with HIPAA and international data protection guidelines. Specifically, all direct personal identifiers (e.g., names, dates of birth, medical record numbers) were removed prior to analysis. Clinical metadata were limited to non-identifiable variables such as age at diagnosis, relapse status, and cytogenetic subtype. Time-to-event data were censored and/or interval-binned to prevent re-identification. No potentially identifying combinations of rare clinical features are present in the dataset. The mass cytometry data include only anonymized expression values without any patient-identifying information.